a Strathclyde Institute of Pharmacy and Biomedical Sciences , University of Strathclyde , Glasgow , UK.
b Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA) , Brussels , Belgium.
Expert Rev Pharmacoecon Outcomes Res. 2019 Jun;19(3):251-261. doi: 10.1080/14737167.2019.1575730. Epub 2019 Feb 15.
In January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): 'Proposal for a Regulation on health technology assessment and amending Directive 2011/24/EU'. A number of stakeholders, including some Member States, welcomed this initiative as it was considered to improve collaboration, reduce duplication and improve efficiency. There were however a number of concerns including its legal basis, the establishment of a single managing authority, the preservation of national jurisdiction over HTA decision-making and the voluntary/mandatory uptake of joint assessments by Member States. Areas covered: This paper presents the consolidated views and considerations on the original Proposal as set by the European Commission of a number of policy makers, payers, experts from pricing and reimbursement authorities and academics from across Europe. Expert commentary: The Proposal has since been extensively discussed at Council and while good progress has been achieved, there are still divergent positions. The European Parliament gave a number of recommendations for amendments. If the Proposal is approved, it is important that a balanced, improved outcome is achieved for all stakeholders. If not approved, the extensive contribution and progress attained should be sustained and preserved, and the best alternative solutions found.
2018 年 1 月,欧盟委员会发布了一份关于卫生技术评估(HTA)的法规提案:“关于卫生技术评估和修订指令 2011/24/EU 的法规提案”。包括一些成员国在内的许多利益相关者对这一倡议表示欢迎,因为这被认为可以提高合作、减少重复和提高效率。然而,也存在一些担忧,包括其法律依据、建立单一管理机构、维护国家对 HTA 决策的管辖权以及成员国自愿/强制采用联合评估。涵盖领域:本文介绍了来自欧洲各地的一些政策制定者、支付方、定价和报销机构的专家以及学者对欧盟委员会提出的原始提案的综合意见和考虑。专家评论:该提案随后在理事会进行了广泛讨论,尽管取得了良好的进展,但仍存在分歧。欧洲议会提出了一些修正案的建议。如果提案获得批准,对所有利益相关者来说,实现一个平衡、改进的结果是非常重要的。如果提案未获得批准,应维持并保留已取得的广泛贡献和进展,并寻找最佳替代解决方案。